[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-disease-risk-factors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-disease-risk-factors":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100541126","glycoxitod-multimodal-vascular-and-target-organ-damage-registry-100541126",false,"NCT06325800","GlycOxiTOD: Multimodal Vascular and Target-Organ Damage Registry","Multimodal Vascular Phenotyping and Target-Organ Damage Using Vascular Imaging, Glyco-Oxidative Biomarkers, and Photoplethysmography in Adults at Increased Cardiovascular Risk: The GlycOxiTOD Observational Registry","GlycOxiTOD","INCLUSION CRITERIA\n\n* Age 18 years or older.\n* Written informed consent to participate in the registry.\n* Undergoing cardiovascular risk or hypertension assessment in a primary-prevention setting.\n* At least one of the following cardiovascular risk conditions:\n\n  * Confirmed hypertension requiring specialist cardiovascular assessment.\n  * A SCORE2 estimated 10-year cardiovascular risk of 2% or higher in participants aged 40 to 69 years, when SCORE2 is applicable.\n  * A SCORE2-OP estimated 10-year cardiovascular risk of 2% or higher in participants aged 70 to 89 years, when SCORE2-OP is applicable.\n  * Type 2 diabetes with at least moderate cardiovascular risk according to SCORE2-Diabetes in participants within its validated age range, or according to guideline-defined clinical risk criteria when SCORE2-Diabetes is not applicable.\n  * Chronic kidney disease confirmed for at least 3 months, defined by an estimated glomerular filtration rate below 60 mL\u002Fmin\u002F1.73 m², a urinary albumin-to-creatinine ratio of 30 mg\u002Fg or higher, or another persistent marker of kidney damage.\n  * Hypertension-mediated target-organ damage or subclinical atherosclerotic vascular disease documented by clinical, laboratory, imaging, or functional assessment.\n  * Confirmed or probable familial hypercholesterolemia.\n  * For participants aged 18 to 39 years or older than 89 years, a documented major cardiovascular risk condition, such as hypertension, type 2 diabetes, chronic kidney disease, familial hypercholesterolemia, or target-organ damage.\n\nEXCLUSION CRITERIA\n\n* Inability or unwillingness to provide written informed consent.\n* Established clinical cardiovascular disease requiring secondary-prevention management, including previous myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, coronary or peripheral revascularization, symptomatic peripheral artery disease, or other established symptomatic cardiovascular disease.\n* Acute or clinically unstable illness that prevents completion of the baseline registry assessment.\n* A medical, technical, cognitive, or logistical condition that prevents completion of the minimum required registry procedures.","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of the GlycOxiTOD observational registry is to improve the early detection and characterization of vascular and other target-organ damage in adults at increased cardiovascular risk.\n\nTarget-organ damage (TOD) means changes in the arteries, heart, kidneys, or other organs that may develop before cardiovascular symptoms or events occur. The registry studies how blood pressure, arterial function, vascular imaging, metabolic and glycoxidative markers, and non-invasive optical signals are related to this early damage.\n\nThe main questions are:\n\n* Which clinical, blood pressure, imaging, and laboratory markers are associated with vascular and other target-organ damage?\n* Can photoplethysmography, a non-invasive optical technique that records changes in blood flow, identify abnormal arterial features?\n* Are new devices, measurement procedures, and signal-analysis methods technically valid, reliable, and reproducible when compared with established clinical methods?\n* Can combinations of clinical, imaging, laboratory, and device-derived measurements improve cardiovascular risk assessment?\n* How do vascular abnormalities and target-organ damage change during follow-up?\n\nResearchers will not assign any treatment as part of this observational registry. Participants will receive assessments that may include:\n\n* Clinical and cardiovascular risk evaluation\n* Office and 24-hour ambulatory blood pressure measurements\n* Blood and urine tests for metabolic, glycation, oxidative stress, and inflammatory markers\n* Non-invasive vascular ultrasound and arterial function measurements\n* Optical photoplethysmography recordings from peripheral or cervical arterial sites\n* Skin measurement of advanced glycation end products\n* Retinal imaging, when available\n* Repeated measurements to assess the reliability and reproducibility of selected devices and procedures\n* Follow-up using clinical visits and medical records to identify changes in target-organ damage and cardiovascular events\n\nThe registry provides a shared clinical research platform for studies on hypertension, vascular imaging, arterial biomechanics, biomarkers, optical technologies, and the technical and methodological validation of non-invasive cardiovascular devices. Its overall aim is to support the development of reliable tools for early cardiovascular risk assessment and prevention.",[26,27,28,29,30],"Hypertension","Target Organ Damage","Heart Disease Risk Factors","Vascular Stiffness","Atherosclerosis",[32,33,34,35,36,37,38,39,40,41,42,43,44],"Photoplethysmography","Vascular Imaging","Carotid Intima-Media Thickness","Carotid Plaque","Arterial Biomechanics","Ambulatory Blood Pressure Monitoring","Advanced Glycation End Products","Oxidative Stress","Cardiovascular Biomarkers","Cardiovascular Risk Assessment","Medical Device Validation","Signal Processing","Noninvasive Vascular Assessment","RECRUITING","2026-08-03",{"date":48,"type":49},"2026-08-05","ACTUAL",{"date":51,"type":49},"2024-01-10",{"date":53,"type":21},"2035-12-31",{"name":55,"class":56},"Complejo Hospitalario Universitario de Santiago","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":57},"100559069","coronary-artery-disease-assessment-strategies-in-tavi-patients-100559069","NCT06559332","Coronary Artery Disease Assessment Strategies in TAVI Patients","Randomized Trial of Coronary Artery Disease Assessment Strategies in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation","CAT","Inclusion:\n\n• Severe aortic stenosis defined by aortic valve area (AVA) ≤1cm2 AND mean gradient ≥40 mmHg or peak velocity ≥4.0 m\u002Fs\n\nOR\n\nif mean gradient \\\u003C40 mmHg and peak velocity (Vmax) \\\u003C4 m\u002Fs and stroke volume indexed to body surface area (SVi) ≤ 35 mL\u002Fm2 and LVEF ≥50% then if CT-derived aortic valve calcium score \\>2000 Agatston units in men, \\>1200 in women\n\nOR\n\nif mean gradient \\\u003C40 mmHg and Vmax \\\u003C4 m\u002Fs and SVi ≤ 35 mL\u002Fm2 and LVEF \\\u003C50% then if CT-derived aortic valve calcification \\>2000 Agatston units in men, \\>1200 in women OR if low-dose dobutamine stress echocardiography with flow reserve (\\>20% increase in stroke volume) and AVA ≤1cm2\n\n* Coronary calcium score ≥ 400 Agatston units (derived from routine pre-TAVI CT) or known coronary artery disease\n* Selected for treatment with transfemoral TAVI.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Concomitant valvular heart disease or ascending aortic aneurysm with indication for surgery or intervention\n* Unprotected left main coronary stenosis \\>50% or left main not evaluable based on coronary computed tomography angiography derived from routine pre-TAVI CT\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%\n* New regional wall motion abnormalities on echocardiography\n* Myocardial infarction in previous 12 months\n* Coronary angiography in previous 12 months\n* Prior left main stenting","70 Years",{"count":68,"type":21},546,"INTERVENTIONAL",[71],"NA","Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.\n\nAs the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit\u002Frisk balance of routine invasive coronary angiography prior to transcatheter aortic valve implantation (TAVI) is unclear.\n\nThe CAT Trial aims to compare a non-invasive risk management strategy to routine invasive coronary angiography for the assessment of coronary artery disease in patients with severe, symptomatic aortic stenosis selected to undergo TAVI with respect to adverse clinical outcomes at 3 years (primary objective) and patient reported outcome measures (secondary objective).",[74,75,28],"Transcatheter Aortic Valve Replacement","Coronary Artery Disease","2026-05-07",{"date":78,"type":49},"2026-05-08",{"date":80,"type":49},"2025-03-11",{"date":82,"type":21},"2032-03-31",{"name":84,"class":56},"Insel Gruppe AG, University Hospital Bern"]